| Intra-Arterial Magnesium Therapy After Mechanical Thrombectomy in Acute Ischemic Stroke (NCT06956521) | Baylor College of Medicine | 2025-06-01 |
| Combined Therapy of Photoelectric Instruments and Human Umbilical Cord Mesenchymal Stem Cells for Pigmentary Disorders (NCT06911281) | Shanghai East Hospital | 2025-06-01 |
| Lentiviral FVIII Gene Therapy (NCT03217032) | Shenzhen Geno-Immune Medical Institute | 2025-06-01 |
| Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation (NCT06970132) | Shouyao Holdings (Beijing) Co. LTD | 2025-06-01 |
| A Study of Linperlisib (YY-20394) in Combination With Rituximab in Patients With Relapsed/Refractory Indolent NHL (NCT06981988) | Jiangsu HengRui Medicine Co., Ltd. | 2025-06-01 |
| Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation (NCT07368634) | Daihong Liu | 2025-06-01 |
| Acupuncture Versus Compound Diclofenac Sodium for Pain Relief in Non-Traumatic Acute Abdominal (NCT06982755) | The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine | 2025-06-01 |
| ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC (NCT07012954) | Sun Yat-sen University | 2025-06-01 |
| A Phase 1 Mass Balance Study of [¹⁴C]SSS17 in Healthy Chinese Males (NCT07025915) | Shenyang Sunshine Pharmaceutical Co., LTD. | 2025-06-01 |
| Adding IL-2 to Tebentafusp to Eradicate Cancer Progression (NCT07063875) | St Vincent's Hospital, Sydney | 2025-06-01 |
| Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus (NCT07374328) | Second Affiliated Hospital of Guangzhou Medical University | 2025-06-01 |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients (NCT06922591) | Tango Therapeutics, Inc. | 2025-05-31 |
| Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases (NCT06163820) | Melanoma and Skin Cancer Trials Limited | 2025-05-31 |
| A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors (NCT06963502) | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 2025-05-30 |
| MR-Guided Radiotherapy Dose Escalation Trial for Esophageal Squamous Cell Carcinoma (NCT07359417) | UMC Utrecht | 2025-05-30 |
| A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P43 in Healthy Male Subjects (NCT06951828) | Celltrion | 2025-05-30 |
| PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas (NCT06961565) | Pasithea Therapeutics Corp. | 2025-05-30 |
| Aprepitant in the Management of Immune Checkpoint Inhibitors Pruritus in Solid Cancer Patients (NCT06931119) | Rabin Medical Center | 2025-05-30 |
| SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites (NCT06991478) | Tianjin Medical University Cancer Institute and Hospital | 2025-05-30 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) (NCT06533579) | Vironexis Biotherapeutics Inc. | 2025-05-30 |
| A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia (NCT07011004) | Memorial Sloan Kettering Cancer Center | 2025-05-30 |
| A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) (NCT06969430) | Debiopharm International SA | 2025-05-30 |
| Short Course Radiation Treatment for Patients With Primary or Locally Recurrent Retroperitoneal Sarcoma Prior to Surgery (NCT06812052) | Brigham and Women's Hospital | 2025-05-29 |
| A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors (NCT06936735) | Hansoh BioMedical R&D Company | 2025-05-29 |
| A Phase 1 Study of PROT-001. (NCT06981299) | Protego Biopharma Pty Ltd | 2025-05-29 |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation (NCT07023731) | Arvinas Inc. | 2025-05-29 |
| Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment (NCT07152288) | Haisco Pharmaceutical Group Co., Ltd. | 2025-05-29 |
| A Study of HDM2005 in Patients With Advanced Solid Tumor (NCT07004296) | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 2025-05-29 |
| Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial (NCT06357676) | OHSU Knight Cancer Institute | 2025-05-29 |
| Pharmacokinetics, Safety and Tolerability of ITF2357 in Participants With Chronic Hepatic Impairment and With Normal Hepatic Function (NCT06736223) | Italfarmaco | 2025-05-29 |
| Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women (NCT06970405) | Regeneron Pharmaceuticals | 2025-05-29 |
| Study of GS-3242 in Participants With HIV-1; Substudy-05 (NCT07001319) | Gilead Sciences | 2025-05-29 |
| Epstein-Barr Virus (EBV) gH/gL/gp42-Ferritin Nanoparticle Vaccine With or Without gp350-Ferritin in Healthy Adults With or Without EBV Infection (NCT06908096) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-05-29 |
| JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration (NCT06973564) | Jacobio Pharmaceuticals Co., Ltd. | 2025-05-29 |
| Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas (NCT07066982) | Essen Biotech | 2025-05-29 |
| Clinical Study for the Evaluation of Safety and Tolerability of SCAI-005 Eye Drops (NCT06969001) | SCAI Therapeutics | 2025-05-29 |
| A Drug-Drug Interaction Study Between HS-10374 Tablets and Drospirenone and Ethinyl Estradiol Tablets(Yasmin®) (NCT07181343) | Hansoh BioMedical R&D Company | 2025-05-28 |
| A Study to Investigate the Impact of Multiple Doses of Itraconazole on AZD5004 in Healthy Participants and Multiple Doses of AZD5004 on Combined Oral Ethinyl Oestradiol and Levonorgestrel in Healthy Female Participants (NCT06942936) | AstraZeneca | 2025-05-28 |
| Padeliporfin VTP Using Robotic Assisted Bronchoscopy in Peripheral Lung Cancer (NCT05918783) | Impact Biotech Ltd | 2025-05-28 |
| A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration (NCT06765980) | Kriya Therapeutics, Inc. | 2025-05-28 |
| HW071021 Monotherapy in Patients With Advanced Solid Tumors (NCT06882135) | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | 2025-05-28 |
| Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) (NCT06160284) | Yale University | 2025-05-28 |
| Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above (NCT07285265) | Suzhou Abogen Biosciences Co., Ltd. | 2025-05-27 |
| Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults (NCT06996184) | CSL Behring | 2025-05-27 |
| Treatment of Persisting Symptoms After Concussion With Psilocybin Assisted Therapy (NCT06615908) | University of Calgary | 2025-05-27 |
| Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) (NCT06564623) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2025-05-27 |
| A Study in Healthy People to Test How Empagliflozin is Taken up in the Body When Taken as a Whole Tablet or Dissolved in Water and Mixed With Food (NCT06962826) | Boehringer Ingelheim | 2025-05-27 |
| Evaluating the Safety and Tolerability of Orally Administered DF-003 in ROSAH Syndrome Patients (NCT06395285) | Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm) | 2025-05-27 |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia (NCT06980428) | AstraZeneca | 2025-05-27 |
| Study of Metronidazole Delayed-Release Capsules in Comparison With Immediate-Release Tablets (Flagyl) for Safety and Pharmacokinetics (NCT07251127) | Gateway Pharmaceutical LLC | 2025-05-27 |
| A Study of LY3867070 in Healthy Participants (NCT07021547) | Eli Lilly and Company | 2025-05-27 |
| Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer (NCT06130826) | City of Hope Medical Center | 2025-05-27 |
| Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer (NCT06782932) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2025-05-27 |
| Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16 (NCT06410131) | Sound Biopharmaceuticals Ltd. | 2025-05-27 |
| Phase I Clinical Trial of Lyophilized Respiratory Syncytial Virus mRNA Vaccine in Adults Aged 18 Years or Above (NCT07289503) | Suzhou Abogen Biosciences Co., Ltd. | 2025-05-27 |
| A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60 (NCT06970756) | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 2025-05-27 |
| Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma (NCT06994572) | Captor Therapeutics S.A. | 2025-05-26 |
| A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer (NCT06921837) | Bolt Biotherapeutics, Inc. | 2025-05-26 |
| A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight (NCT07004322) | Novo Nordisk A/S | 2025-05-26 |
| A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors (NCT06943677) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2025-05-26 |
| To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions. (NCT07098585) | Humanis Saglık Anonim Sirketi | 2025-05-26 |
| The Mass Balance and Biotransformation Study of [14C] VC005 in Chinese Healthy Adult Male Volunteers (NCT06974292) | Jiangsu vcare pharmaceutical technology co., LTD | 2025-05-26 |
| A Phase Ib/II Clinical Study of Regorafenib Combined With Toripalimab and Albumin-bound Paclitaxel for the Third-line Treatment of Advanced Pancreatic Cancer (NCT07040228) | Junjie Hang | 2025-05-26 |
| A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL (NCT06966154) | Fudan University | 2025-05-26 |
| A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) (NCT07072169) | Ruijin Hospital | 2025-05-26 |
| Effectiveness of Topical Application of Melatonin On Bone Density and Implant Stability In Immediate Implantation (NCT07003243) | University of Baghdad | 2025-05-26 |
| The Phase 1, Open-label, PET Trial Designed to Investigate the Effect of AZD2389 on FAP Occupancy in the Liver in Participants With Advanced Liver Fibrosis. (NCT07069725) | AstraZeneca | 2025-05-26 |
| A Phase 1 Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetics of AS-S603 in Healthy Participants (NCT06786676) | Amyloid Solution Inc | 2025-05-26 |
| A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) (NCT06941272) | Merck Sharp & Dohme LLC | 2025-05-26 |
| A Phase 1 MAD Study of KINE-101 in Healthy Volunteers (NCT07324642) | Kine Sciences Co., Ltd. | 2025-05-26 |
| Treatment of Moyamoya Disease With iPSC-derived Exosomes (NCT07065409) | Huaqiu Zhang | 2025-05-26 |
| A Clinical Research of CD70-targeted CAR-NKT Cells (CGC738) Therapy in RCC (NCT06870279) | RenJi Hospital | 2025-05-25 |
| Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration (NCT07003555) | Beijing GoBroad Hospital | 2025-05-25 |
| Phase I-II Clinical Study of Taurine for External Use in the Prevention and Treatment of Acute Radiation Skin Injury (NCT06847555) | Shandong Cancer Hospital and Institute | 2025-05-25 |
| Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration (NCT07003568) | Beijing GoBroad Hospital | 2025-05-25 |
| To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults (NCT06933459) | AJU Pharm Co., Ltd. | 2025-05-24 |
| A First in Human Study of TT5 in Single and Multiple Ascending Doses in Healthy Volunteers and Surgical Patients (NCT06789861) | Tafalgie Therapeutics | 2025-05-23 |
| XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation (NCT06936527) | NovaOnco Therapeutics Co., Ltd. | 2025-05-23 |
| A Phase I Clinical Trial to Evaluate the Single Dose Ascending and Food Effects of PG-033 in Healthy Adults (NCT07013097) | Prime Gene Therapeutics Co., Ltd. | 2025-05-23 |
| The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies (NCT07002112) | The First Affiliated Hospital with Nanjing Medical University | 2025-05-23 |
| A Clinical Trial of Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried (NCT07021703) | Ningbo Rongan Biological Pharmaceutical Co., Ltd. | 2025-05-23 |
| Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer (NCT06903377) | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 2025-05-23 |
| A Study in Healthy Participants to Investigate Relative Bioavailability of AZD5004 in Three Solid Oral Formulations (NCT06996886) | AstraZeneca | 2025-05-22 |
| A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (NCT06880354) | Institute of Hematology & Blood Diseases Hospital, China | 2025-05-22 |
| An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors (NCT06942143) | Guangzhou FineImmune Biotechnology Co., LTD. | 2025-05-22 |
| Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) (NCT06504160) | National Institute of Allergy and Infectious Diseases (NIAID) | 2025-05-22 |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression (NCT06682793) | A2 Biotherapeutics Inc. | 2025-05-22 |
| A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer (NCT06974929) | Jiangsu HengRui Medicine Co., Ltd. | 2025-05-22 |
| A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia (NCT06810583) | St. Jude Children's Research Hospital | 2025-05-22 |
| Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT06454409) | City of Hope Medical Center | 2025-05-21 |
| Study on the Mass Balance of [14C]HRS-8427 for Injection in Healthy Chinese Subjects (NCT07049562) | Jiangsu HengRui Medicine Co., Ltd. | 2025-05-21 |
| A Study of HBS-201 (Pitolisant Delayed-release) (NCT07051252) | Harmony Biosciences Management, Inc. | 2025-05-21 |
| Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets (NCT07213895) | Humanis Saglık Anonim Sirketi | 2025-05-21 |
| Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL (NCT06863259) | Children's Hospital Medical Center, Cincinnati | 2025-05-21 |
| AK129 Combination Therapy for Advanced Solid Tumors (NCT06943820) | Akeso | 2025-05-21 |
| Bioequivalence Study of Bempedoic Acid 180 mg Film Coated Tablet and Nilemdo® (Bempedoic Acid) 180 mg Film-coated Tablets (NCT07170852) | Humanis Saglık Anonim Sirketi | 2025-05-21 |
| Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors (NCT06902350) | Chipscreen Biosciences, Ltd. | 2025-05-21 |
| Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas (NCT06964737) | Ohio State University Comprehensive Cancer Center | 2025-05-21 |
| A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z (NCT06929260) | AstraZeneca | 2025-05-21 |
| Combination of Chemotherapy and Adaptive MR-Guided Radiotherapy to Improve Outcomes in Patients With Esophageal Adenocarcinoma (NCT07359443) | UMC Utrecht | 2025-05-21 |